We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
The focus will be primarily on revenue growth amid the pandemic for Tilray, Inc. (TLRY - Free Report) when it reports first-quarter results.
In the last reported quarter, the company beat earnings expectations by 42.86%. The company has a decent track record. Tilray missed earnings estimates in two of the last four quarters and beat in the remaining two, the average negative surprise being 1.66%.
Let us see how things have shaped up prior to this announcement.
Our proven model predicts an earnings beat for Tilray this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is +11.48%.
Zacks Rank: It currently carries a Zacks Rank #3.
Factors at Play
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids.
Revenues grew 20.5% year over year in the last reported quarter to $56.6 million, driven by revenue growth across core businesses, and similar levels of growth have most likely prevailed in the quarter under review. Cannabis segment revenues increased 46%, driven by the acceleration of International Medical sales (+191%) and Canadian Adult-Use sales (+49%). Canadian medical sales grew 26%. Similar trends have likely prevailed in the first quarter. However, Hemp segment revenue ads decreased 18% year over year due to a shift to private-label products with a large customer and the impact of COVID-related changes on consumers’ shopping patterns, a trend that has most likely continued in the to-be-reported quarter.
Total cannabis kilogram equivalents sold decreased 54%, almost entirely due to the reduction of bulk sales, and the first quarter has most likely witnessed the same.
Gross margin increased to 29% from 7% in the previous quarter and the same might have been the trend in the to-be-reported quarter.
A Key Recent Development
Tilray completed its previously announced merger with Aphria Inc. The combined company is one of the leading cannabis-focused consumer packaged goods companies with the largest global geographic footprint in the industry. Each Aphria shareholder received 0.8381 of a Tilray Share for each Aphria common share held on Apr 30, 2021. The operational efficiencies from this combination are expected to generate approximately $81 million of annual pre-tax cost-saving synergies for the company within eighteen months.
Share Price Performance
Tilray’s stock has rallied 111.6% in the year so far against the industry’s decline of 8.4%.
Other Stocks to Consider
Here are a few other stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Kala Pharmaceuticals, Inc. (KALA - Free Report) has an Earnings ESP of +3.45% and a Zacks Rank #2.
Incyte (INCY - Free Report) has an Earnings ESP of +8.48% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
The focus will be primarily on revenue growth amid the pandemic for Tilray, Inc. (TLRY - Free Report) when it reports first-quarter results.
In the last reported quarter, the company beat earnings expectations by 42.86%. The company has a decent track record. Tilray missed earnings estimates in two of the last four quarters and beat in the remaining two, the average negative surprise being 1.66%.
Let us see how things have shaped up prior to this announcement.
Tilray, Inc. Price, Consensus and EPS Surprise
Tilray, Inc. price-consensus-eps-surprise-chart | Tilray, Inc. Quote
Why a Likely Positive Surprise
Our proven model predicts an earnings beat for Tilray this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is +11.48%.
Zacks Rank: It currently carries a Zacks Rank #3.
Factors at Play
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids.
Revenues grew 20.5% year over year in the last reported quarter to $56.6 million, driven by revenue growth across core businesses, and similar levels of growth have most likely prevailed in the quarter under review. Cannabis segment revenues increased 46%, driven by the acceleration of International Medical sales (+191%) and Canadian Adult-Use sales (+49%). Canadian medical sales grew 26%. Similar trends have likely prevailed in the first quarter.
However, Hemp segment revenue ads decreased 18% year over year due to a shift to private-label products with a large customer and the impact of COVID-related changes on consumers’ shopping patterns, a trend that has most likely continued in the to-be-reported quarter.
Total cannabis kilogram equivalents sold decreased 54%, almost entirely due to the reduction of bulk sales, and the first quarter has most likely witnessed the same.
Gross margin increased to 29% from 7% in the previous quarter and the same might have been the trend in the to-be-reported quarter.
A Key Recent Development
Tilray completed its previously announced merger with Aphria Inc. The combined company is one of the leading cannabis-focused consumer packaged goods companies with the largest global geographic footprint in the industry. Each Aphria shareholder received 0.8381 of a Tilray Share for each Aphria common share held on Apr 30, 2021. The operational efficiencies from this combination are expected to generate approximately $81 million of annual pre-tax cost-saving synergies for the company within eighteen months.
Share Price Performance
Tilray’s stock has rallied 111.6% in the year so far against the industry’s decline of 8.4%.
Other Stocks to Consider
Here are a few other stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Ironwood Pharmaceuticals (IRWD - Free Report) has an Earnings ESP of +0.25% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kala Pharmaceuticals, Inc. (KALA - Free Report) has an Earnings ESP of +3.45% and a Zacks Rank #2.
Incyte (INCY - Free Report) has an Earnings ESP of +8.48% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>